Apricitabine

N/A

Report date: 2026/03/16 20:01:47
NME

Base Information

Drug NameApricitabine
Drug Alias Name阿立他滨apricitabineapricitabinaapricitabinum(-)-BCH-10652 +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesShire Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovita HealthcareAvexa Ltd
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeJ05AB
Related LinksWikipedia